Testing PathFinder 1.0 software to spot retinal abnormalities on eye scans
Tests how well PathFinder 1.0 finds retinal abnormalities on eye scans in adults.
Plain-language title generated from the registry record
Registry title: (CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
Key facts
- Where
- Fort Lauderdale, Kansas City, Mountain View, Portland, San Francisco, and Tucson, United StatesSee the 6 sites
Where in United States
- Nova Southeastern University; College of OptometryFort Lauderdale, United StatesTaking people
- Moyes Eye CenterKansas City, United StatesTaking people
- Northern California Retina Vitreous AssociatesMountain View, United StatesTaking people
- Eyecare Medical GroupPortland, United StatesTaking people
- Premier Eyecare of San FranciscoSan Francisco, United StatesNo longer taking part
- Retina AssociatesTucson, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Carl Zeiss Meditec-Dublin CoCe
- Trial code
- NCT07680244
- Record updated
- 28 August 2026
- Original description
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.Read full original descriptionShow less
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
Inclusion: Able and willing to make the required study visits; Able and willing to give written informed consent and follow study instructions; Able and willing to complete ophthalmic imaging; Adults 18 years of age or older; The subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area):; Group A; Subjects with absence of macular abnormalities Group B; Subjects with Disruption of the vitreoretinal interface (VRI); Subjects with Intraretinal hyporeflective space (IRHS); Subjects with Subretinal hyporeflective space (SRHS); Subjects with IS/OS (Ellipsoid Zone) disruption; Subjects with Retinal Pigment Epithelium (RPE) elevation; Subjects with Retinal Pigment Epithelium (RPE) atrophy; Other abnormalities.
Exclusion: Inability to undergo the required tests; Unable to give consent or follow study instructions; Inability to fixate that precludes obtaining acceptable macula scans in the study eye; Visudyne (verteporfin) injection within the last 48 hours in the study eye; Pilocarpine or Vuity use within the last 24 hours in the study eye; Dense media opacity precluding adequate visualization of the retina in the study eye; Vitreous floaters that preclude obtaining acceptable scans in the study eye.